- Home
- SOPH vs OABI Comparison
SOPH vs OABI Comparison
Compare SOPH & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- OABI
- Stock Information
- Founded
- SOPH 2011
- OABI 2012
- Country
- SOPH Switzerland
- OABI United States
- Employees
- SOPH N/A
- OABI N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- OABI Health Care
- Exchange
- SOPH Nasdaq
- OABI Nasdaq
- Market Cap
- SOPH 214.9M
- OABI 240.5M
- IPO Year
- SOPH 2021
- OABI N/A
- Fundamental
- Price
- SOPH $3.46
- OABI $2.01
- Analyst Decision
- SOPH Buy
- OABI Strong Buy
- Analyst Count
- SOPH 1
- OABI 3
- Target Price
- SOPH $7.00
- OABI $6.67
- AVG Volume (30 Days)
- SOPH 88.9K
- OABI 480.3K
- Earning Date
- SOPH 08-05-2025
- OABI 08-06-2025
- Dividend Yield
- SOPH N/A
- OABI N/A
- EPS Growth
- SOPH N/A
- OABI N/A
- EPS
- SOPH N/A
- OABI N/A
- Revenue
- SOPH $69,688,000.00
- OABI $23,027,000.00
- Revenue This Year
- SOPH $16.13
- OABI N/A
- Revenue Next Year
- SOPH $23.80
- OABI $45.02
- P/E Ratio
- SOPH N/A
- OABI N/A
- Revenue Growth
- SOPH 7.32
- OABI 6.05
- 52 Week Low
- SOPH $2.58
- OABI $1.22
- 52 Week High
- SOPH $4.92
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- SOPH 56.10
- OABI 54.14
- Support Level
- SOPH $2.96
- OABI $1.69
- Resistance Level
- SOPH $3.24
- OABI $2.09
- Average True Range (ATR)
- SOPH 0.26
- OABI 0.11
- MACD
- SOPH -0.00
- OABI -0.01
- Stochastic Oscillator
- SOPH 84.53
- OABI 80.25
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.